

Inhibitory effects on human leukemic U937 cells and immunomodulatory activities of royal jelly

林宥彤、張基郁

E-mail: 321483@mail.dyu.edu.tw

ABSTRACT

In this study, the royal jelly (RJ) was treated with four manners, including phosphate buffer solution (PBS) extraction, alkali extraction, heating, and enzymatic digestion, to investigate its inhibitory effect on human leukemic U937 cells and immunomodulatory activities. The results were as followings: 1. The growth of U937 cells incubated with the royal jelly of different treatments for 5 days are more inhibited than those incubated for 3 days. The fresh royal jelly shows the most effective on the growth inhibition of U937 cells via direct model (its inhibition rate is 36.65 %). The royal jelly of enzymatic digestion shows the most effective on the growth inhibition of U937 cells via indirect model (its inhibition rate is 62.39 %). 2. The cytokine contents secreted in the mononuclear cell-condition medium (MNC-CM) with royal jelly of different treatments are higher than the PBS and the medium groups. For the IL-1 β secretion, the MNC-CM with alkali extract shows the highest value (1373.35 pg/mL). For the IFN- γ secretion, the MNC-CM with enzymatic digestion shows the highest value (34448 pg/mL). For the TNF- α secretion, the MNC-CM with alkali extract shows the highest value (5287.08 pg/mL). 3. For the NO secretion, the MNC-CMs with the royal jelly of different treatments were incubated for 3 days, their NO contents were higher than those of the PBS and the medium groups, and the MNC-CM with alkali extract had the highest NO content (1.96 μ M/mL). However, the MNC-CM with enzymatic digestion had a lower NO content than the PBS and medium groups. 4. For the growth index of MNC, the royal jelly of different treatments at a certain concentration can stimulate the growth of MNC when compared with the PBS and the medium groups. The RJ of heat treatment shows the highest growth index (1.16).

Keywords : Royal Jelly、Leukemic U937 Cell、cytokine、immunomodulatory activity

Table of Contents

授權書iii 中文摘要iv 英文摘要vi 誌謝viii 目錄x 圖目錄xiv 表目錄xv 附錄目錄xvii 符號說明xviii 1. 緒論1 2. 文獻回顧2 2.1 蜂王乳2 2.1.1 蜂王乳之生成2 2.1.2 蜂王乳之蛋白質成分及細胞活性2 2.1.3 蜂王乳之藥理作用3 2.2 癌症4 2.2.1 癌症之定義4 2.2.2 一般癌症形成的主要原因4 2.2.3 癌症治療5 2.2.4 白血病分類與治療6 2.2.5 人類白血病細胞株(U937)7 2.3 免疫系統8 2.3.1 先天或非專一性免疫防禦機制8 2.3.2 後天或專一性免疫防禦機制10 2.4 免疫系統的細胞12 2.4.1 T淋巴球12 2.4.2 B淋巴球13 2.4.3 自然殺手細胞14 2.4.4 巨噬細胞14 2.5 細胞激素15 2.5.1 腫瘤壞死因子19 2.5.2 介白素20 2.5.3 干擾素20 2.5.4 一氧化氮21 3. 材料與方法23 3.1 實驗材料23 3.1.1 蜂王乳23 3.1.2 實驗細胞23 3.1.3 實驗藥品23 3.1.4 儀器設備24 3.2 實驗方法26 3.2.1 實驗流程26 3.2.2 蜂王乳之處理26 3.2.3 基本成分分析28 3.2.4 NuPAGE Bis-Tris gel 電泳法30 3.2.5 蜂王乳經由直接模式對U937細胞抑制作用之實驗32 3.2.6 蜂王乳經由間接模式對U937細胞抑制作用之實驗34 3.2.7 樣品-單核細胞條件培養液細胞激素之含量測定36 3.2.8 樣品-單核細胞條件培養液一氧化氮含量之測定38 3.2.9 經由樣品刺激後人類單核細胞之生長比例39 3.3 統計分析40 4. 結果與討論41 4.1 蜂王乳組成分及蛋白質定量分析41 4.2 電泳分析45 4.3 不同處理蜂王乳對白血病細胞U937生長之直接抑制效果47 4.4 不同處理蜂王乳對白血病細胞U937生長之間接抑制效果51 4.5 不同處理蜂王乳刺激單核球細胞分泌細胞激素之能力58 4.5.1 不同處理蜂王乳刺激單核球細胞分泌IL-1 β 之能力58 4.5.2 不同處理蜂王乳刺激單核球細胞分泌IFN- γ 之能力63 4.5.3 不同處理蜂王乳刺激單核球細胞分泌TNF- α 之能力67 4.5.4 分析LPS對條件培養液中細胞激素含量之影響72 4.6 不同處理蜂王乳刺激單核球細胞分泌NO之能力75 4.7 不同處理蜂王乳刺激人類單核細胞之生長比例78 5. 結論84 參考文獻87 圖目錄 圖2.1 細胞激素的信號傳遞途徑17 圖2.2 細胞激素的特有性18 圖3.1 實驗流程圖27 圖4.1 不同處理蜂王乳之電泳分析46 圖4.2 分析添加LPS對不同處理之蜂王乳條件培養液中IL-1 β 含量之影響73 圖4.3 分析添加LPS對不同處理之蜂王乳條件培養液中TNF- α 含量之影響74 圖4.4 蜂王乳刺激人類單核細胞1和3天後之細胞生長率79 圖4.5 加熱處理之蜂王乳刺激人類單核細胞1和3天後之細胞生長率80 圖4.6 磷酸緩衝溶液萃取之蜂王乳刺激人類單核細胞1和3天後之細胞生長率81 圖4.7 鹼萃取之蜂王乳刺激人類單核細胞1和3天後之細胞生長率82 圖4.8 模擬胃腸道酵素消化之蜂王乳刺激人類單核細胞1和3天後之細胞生長率83 表目錄 表2.1 免疫細胞於專一性及非專一性免疫之角色9 表2.2 腫瘤細胞的辨識與毒殺於體液性及細胞細免疫機制11 表3.1 NuPAGE 樣品之製備31 表4.1 生鮮蜂王乳之一般組成42 表4.2 不同處理蜂王乳之蛋白質含量43 表4.3 不同處理蜂王乳之收率44 表4.4 不同處理蜂王乳以直接作用模式對U937細胞培養3天之生長抑制率之影響49 表4.5 不同處理蜂王乳以直接作用模式對U937細胞培養5天之生長抑制率之影響50 表4.6 不同處理蜂王乳刺激人類單核細胞1天後對U937細胞培養3天之生長抑制率之影響54 表4.7 不同處理蜂王乳刺激人類單核細胞1天後對U937細胞培

養5天之生長抑制率之影響55 表4.8 不同處理蜂王乳刺激人類單核細胞3天後對U937細胞培養3天之生長抑制率之影響56
表4.9 不同處理蜂王乳刺激人類單核細胞3天後對U937細胞培養5天之生長抑制率之影響57 表4.10 以不同處理蜂王乳刺激人類單核球細胞1天後之IL-1 含量61 表4.11 以不同處理蜂王乳刺激人類單核球細胞3天後之IL-1 含量62 表4.12 以不同處理蜂王乳刺激人類單核球細胞1天後之IFN- γ 含量65 表4.13 以不同處理蜂王乳刺激人類單核球細胞3天後之IFN- γ 含量66
表4.14 以不同處理蜂王乳刺激人類單核球細胞1天後之TNF- α 含量70 表4.15 以不同處理蜂王乳刺激人類單核球細胞3天後之TNF- α 含量71 表4.16 以不同處理蜂王乳刺激人類單核球細胞1天後之NO含量76 表4.17 以不同處理蜂王乳刺激人類單核球細胞3天後之NO含量77 表5.1 不同處理之蜂王乳在本研究中各實驗之最佳濃度86 附錄目錄 附錄一 人類IL-1 β 之標準曲線99 附錄二 人類IFN- γ 之標準曲線100 附錄三 人類TNF- α 之標準曲線101 附錄四 一氧化氮以NaNO₂測定表示之標準曲線102

REFERENCES

- 1.于善謙、王洪梅、朱乃碩、葉容。2001。免疫學導論。九州圖書文物有限公司。
- 2.盧冠霖、尤封陵、王姿文、詹明修、張讚昌。2002。新編免疫學。永大書局。
- 3.行政院衛生署。2008。97年死因統計表。
- 4.許清祥。2004。免疫學。合記圖書出版社。
- 5.林勝豐。2002。認識癌症。高醫醫訊。22 : 1-6。
- 6.曹巧吟。2003。樟芝中免疫調節蛋白的純化與其生理活性之探討。國立台灣大學園藝學研究所碩士論文，台北。
- 7.宮華婷。2006。初乳之免疫調節作用及對人類白血病細胞(U937)之抑制效果。國立台灣大學食品科技研究所碩士論文，台北。
- 8.沈美伶。2004。Resveratrol誘導人類血癌細胞之分化與凋亡。私立大葉大學生物產業科技學系碩士論文，彰化。
- 9.陳南吟。2008。浸液培養條件對黃金銀耳菌(*Tremella mesenterica*)型態、多醣體生成及其生物活性之影響。私立大葉大學生物產業科技學系碩士論文，彰化。
- 10.梁啟榮。2008。孤兒G蛋白偶聯受體，GPCR109B及GPCR43，在藥物誘導K562人類血癌細胞株分化過程扮演不同角色。私立大葉大學生物產業科技學系碩士論文，彰化。
- 11.郭雅婷。2007。香椿(TSL-1)及樟芝(AC-10)對人類急性骨髓血癌細胞凋亡及細胞周期的機制探討。私立中國醫藥大學營養研究所，台中。
- 12.王韻寧。2004。黑豆浸泡液誘導人類白血病細胞(U937)分化之分析及對Balb/c鼠皮下移植CT26腫瘤之抑制效果。國立台灣大學食品科技研究所，台北。
- 13.徐麗嵐。2002。以柳松菇與鴻喜菇誘導人類白血病細胞(U937)分化及對Balb/c鼠皮下移植CT26腫瘤之抑制效果。國立台灣大學食品科技研究所，台北。
- 14.Albert, S., & Klaudiny, J. 2004. The MRJP/YELLOW protein family of *Apis mellifera*: Identification of new members in the EST library. *Journal of Insect Physiology*. 50 : 51 – 59.
- 15.Anichini, A., Fossati, G., & Parmiani, G. 1987. Clonal analysis of the cytolytic T cell response to human tumor. *Immunology Today*. 8 : 385-389.
- 16.AOAC. (1995). Official method of Analysis, 14th ed. Association of Official American Chemists, Washington, D.C., U.S.A.
- 17.Benjamini, E., Coico, R., & Sunshine, G. 2000. Immunology : a short course, 4 th ed. New York.
- 18.Beutler, B., & Cerami, A. 1989. The biology of cachectin/TNF : a primary mediator of the host response. *Annual Review of Immunology*. 7 : 625-55.
- 19.Bilikova, K., Hanes, J., Nordhoff, E., Saenger, W., Klaudiny, J., & Simuth, J. 2002. Apisimin, a new serine-valine-rich peptide from honeybee (*Apis mellifera L.*) royal jelly: Purification and molecular characterization. *FEBS Letters*. 528 : 125 – 129.
- 20.Bogdan, C. 2000. The function of nitric oxide in the immune system. in *Handbook of Experimental Pharmacology*. volume: Nitric oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society (ed. Mayer, B.). p. 443 – 492.
- 21.Borish, L. C., & Steinke, J. W. 2003. Cytokines and chemokines. *Journal of Allergy and Clinical Immunology*. 111 : 460-475.
- 22.Carswell, E., Old, L., Kassel, R., Green, N., Fiore, N., & Williamson, B. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. *Proceedings of the National Academy of Sciences of the United States of America*. 72 : 3666-3670.
- 23.Cellier, M. F. M., Taimi, M., Chateau, M. T., Cannat, A., & Marti, J. 1993. Thermal stress as an inducer of differentiation of U937 cells. *Leukemia Research*. 17 : 649-656.
- 24.Cerretti, D. P., Kozlosky, C. J., Mosley, N., Van-Ness, K., Greenstreet, T. A., et al. 1992. Molecular cloning of the interleukin-1 β -converting enzyme. *Science*. 256 : 97-100.
- 25.Chen, C. S., & Chen, S. Y. 1995. Changes in protein-components and storage stability of royal jelly under various conditions. *Food Chemistry*. 54 : 195 – 200.
- 26.Chen, Y. Y. & Chang, H. M. 2004. Antiproliferative and differentiating effects of polysaccharide fraction from fu-ling (*Poria cocos*) on human leukemic U937 and HL-60 cells. *Food Chemistry Toxicology*. 42 : 759 – 769.
- 27.Colin, G. A., & Elfenbein, G. J. 2003. The latest treatment advances for acute myelogenous leukemia. *Medicine and Health Rhode Island*. 86 : 243-6.
- 28.Dinarello, C. A. 1991. Interleukin-1 and interleukin-1 antagonism. *Blood*. 77 : 1627-1752.
- 29.Dinarello, D. P., & Wolff, S. M. 1993. The role of interleukin-1 in disease. *New England Journal of Medicine*. 328 : 106-13.
- 30.Dixit, P. K., & Patel, N.G. 1964. Insulin-like activity in larval foods of the honeybee. *Nature*. 202 : 189 – 190.
- 31.Drapeau, M. D., Albert, S., Kucharsk, R., Prusko, C., & Maleszka, R. 2006. Evolution of the yellow/major royal jelly protein family and the emergence of social behavior in honey bees. *Genome Research*. 16 : 1385 – 1394.
- 32.Fujii, A., Kobayashi, S., Kuboyama, N., Furukawa, Y., Kaneko, Y., Ishihama, S., Yamamoto, H., & Tamura, T., 1990. Augmentation of wound healing by royal jelly (RJ) in streptozotocin-diabetic rats. *Japanese Journal of Pharmacology*. 53 : 331 – 337.
- 33.Goldsby, R. A., Kindt, T. J., Osborne, B. A., & Kuby, J. 2003. Immunology. 5 th ed. W. H. Freeman Co., New York.
- 34.Howe, S. R., Dimick, P. S., & Benton, A. W. 1985. Composition of freshly harvested and commercial royal jelly. *Journal of Apicultural Research*. 24: 52 – 61.
- 35.Isaacs, A., & Lindenmann, J. 1957. Virus interference I. The interferon. *Proceedings of the Royal Society of London B Biology Science*. 147: 258-267.
- 36.Jantova, S., Cipak, L., Letasiova, S. 2007. Berberine induces apoptosis through a mitochondrial/caspase pathway in human promonocytic U937 cells. *Toxicol in Vitro*. 21: 25-31.
- 37.Kamakura, M., & Fukushima, M. 2002. Inhibition of specific degradation of 57-kDa protein in royal jelly during storage by ethylenediaminetetraacetic acid. *Bioscience Biotechnology and Biochemistry*. 66 : 175 – 178.
- 38.Kamakura, M., Mitani, N., Fukuda, & Fukushima, M. 2001. Antifatigue effect of fresh royal jelly in mice. *Journal of Nutritional Science and Vitaminology*. 47 : 394 – 401.
- 39.Kamakura, M.,

Suenobu, N., & Fukushima, M. 2001. Fifty-seven-kDa protein in royal jelly enhances proliferation of primary cultured rat hepatocytes and increases albumin production in the absence of serum. *Biochemical and biophysical research communications*. 282 : 865 – 874. 40.Kamijo, R., Takeda, K., Nagumo, M., & Konno, K. 1990. Effects of combinations of transforming growth factor- β and tumor necrosis factor on induction of differentiation of human myelogenous leukemic cell lines. *Journal of Immunology*. 144 : 1311-1316. 41.Kaushansky, K., Lin, N., & Adamson, J.W. 1988. Interleukin-1 stimulates fibroblasts to synthesize granulocyte- macrophage and granulocyte colony-stimulating factors. Mechanism for the hematopoietic response to inflammation. *Journal of Clinical Investigation*. 81 : 92-97. 42.Kikuchi, A., Kaibuchi, K., Hori, Y., Nonaka, H., Sakoda, T., Kawamura, M., Mizuno, T. & Takai, Y. 1992. Molecular cloning of the human cDNA for a stimulatory GDP/GTP exchange protein for c-Ki-ras p21 and smg p21. *Oncogene*. 7 : 289-293. 43.Kimura, M., kimura, Y., Tsumura, K., Sugimoto, H., Yamada, H., et al. 2003. 350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the betal-3galactosylated N-glycan: Analysis of the N-glycosylation site. *Bioscience Biotechnology and Biochemistry*. 67 : 2055-2058. 44.Kohno, K., Okamoto, I., Sano, O., Arai, N., Iwaki, K., Ikeda, M., et al. 2004. Royal jelly inhibits the production of proinflammatory cytokines by activated macrophages. *Bioscience Biotechnology and Biochemistry*. 68 : 138 – 145. 45.Kolb, H., & Kolb-Bachofen, V. 1992. Type 1 (insulin-dependent) diabetes mellitus and nitric oxide. *Diabetologia*. 35: 796-797. 46.Koya-Miyata, S., Okamoto, I., Ushio, S., Iwaki, K., Ikeda, M., & Kurimoto, M., 2004. Identification of a collagen production-promoting factor from an extract of royal jelly and its possible mechanism. *Bioscience Biotechnology and Biochemistry*. 68 : 767 – 773. 47.Kramer, K. J., Tager, H. S., Childs, C. N., & Speirs, R. D. 1977. Insulin-like hypoglycemic and immunological activities in honeybee royal jelly. *Journal of Insect Physiology*. 23 : 293 – 295. 48.Krell, R. 1996. Value-Added Products From Beekeeping. *Food and Agriculture Organisation of the UN, Agriculture Services Bulletin*.124. 49.Kumar, V., Cotran, R. S., Robbins, S. L., & Perkins, J. A. 1997. *Basic Pathology* (6 th ed.). Philadelphia : aunder. 4-20 : 132-174. 50.Lander, H. M., Sehajpal, P., Levine, D. M. & Novogrodsky, A. 1993. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compound. *Journal of Immunology*. 150 : 1509-1516. 51.Lazarov, S., Balutsov, M., & Ianev, E. 2000. The role of bacterial endotoxins, receptors and cytokines in the pathogenesis of septic (endotoxin) shock. *Vutr. Boles*. 32 : 33 – 40. 52.Legdeur, M. C., Bontje, P. M., Ossenkoppele, G. J., Beelen, R. H., van de Loosdrecht, A. A., Broekhoven, M. G., Langenhuijsen, M. M., Thijssen, S. F., Hofstee, H., & Schuurhuis, G. J. 1996. The role of BCL-2 and bax protein in monocyte-mediated apoptosis in human leukemic cell lines. *Experimental Hematology*. 24 : 1530-1539. 53.Li, J., Wang, T., Zhang, Z., & Pan, Y. 2007. Proteomic analysis of royal jelly from three strains of western honeybees (*Apis mellifera*). *Journal of Agricultural and Food Chemistry*. 55 : 8411 – 8422. 54.Lieu, C. W., Lee, S. S., & Wang, S. Y. 1992. The effect of Ganoderma lucidum on induction of differentiation in leukemic U937 cells. *Anticancer Research*. 12 : 1211-1216. 55.Lotem, J., & Sachs, L. 1987. Regulation of cell-surface receptors for hematopoietic differentiation-inducing protein MGI-2 on normal and leukemic myeloid cells. *International Journal of Cancer. Journal International Du Cancer*. 40 : 532-539. 56.Maines, M.D., Costa, L.G., Reed, D.J., Sassa, S., & Sipes, I.G. 1999. *Current protocols in toxicology*. John Wiley and Sons, New York. 57.Mannel, D. N. & Echtenacher, B. 2000. TNF in the inflammatory response. *Chemistry of Immunology*. 74 : 141 – 161. 58.Marshall, N. J., Goodwin, C. J., & Holt, S. J. 1995. A critical assessmet of the use of microculture tetrazolium assay to measure cell growth and function. *Growth Regul.* 5 : 69-84. 59.Mishima, S., Suzuki, K. M., Isohama, Y., Kuratsu, N., Araki, Y., Inoue, M., et al. 2005. Royal jelly has estrogenic effects in vitro and in vivo. *Journal of Ethnopharmacology*. 101 : 215 – 220. 60.Morgera, S., Haase, M., Rocktaschel, J., Bohler, T., Heymann, C. V., Vargas-Hein, O., Krausch, D., Zuckermann-Becker, H., Muller, J. M., Kox, W. J., & Neumayer, H. H. 2003. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. *Nephrol Dial Transplant*. 18 : 2570 – 2576. 61.Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of Immunology Methods*. 65 : 55-63. 62.Munker, R., & Koeffler, H. P. 1987. Tumor necrosis factor: recent advances. *Klin Wochenschr*. 65 : 345-52. 63.Nagai, T., & Inoue, R. 2003. Preparation and the functional properties of water extract and alkaline extract of royal jelly. *Food Chemistry*. 84 : 181-186. 64.Nakadai, A., Li, Q., & Kawada, T. 2006. Chlorpyrifos induces apoptosis in human monocyte cell line U937. *Toxicology*. 224 : 202-9. 65.Nakajin, S., Okiyama, K., Yamashita, S., Akiyama, Y., & Shinoda, M. 1982. Effect of royal jelly on experimental hypercholesterolemia in rabbits. *Yakugaku Zasshi. Journal of the Pharmaceutical Society of Japan*. 36 : 65 – 69. 66.Nakaya, M., Onda, H., Sasaki, K., Yukiyoshi, A., Tachibana, H., & Yamada, K. 2007. Effect of royal jelly on bisphenol A-induced proliferation of human breast cancer cells. *Bioscience Biotechnology and Biochemistry*. 71 : 253 – 255. 67.Naldini, A., Pucci, A., & Carraro, F. 2001. Hypoxia induces the expression and release of interleukin 1 receptor antagonist in mitogen-activated mononuclear cells. *Cytokine*. 13 : 334 – 341. 68.Narita, Y., Nomura, J., Ohta, S., Inoh, Y., Suzuki, K. M., Araki, Y., et al. 2006. Royal jelly stimulates bone formation: physiologic and nutrigenomic studies with mice and cell lines. *Bioscience Biotechnology and Biochemistry*. 70 : 2508 – 2514. 69.Okamoto, I., Taniguchi, Y., Kunikata, T., Kohno, K., Iwaki, K., Ikeda, M., et al. 2003. Major royal jelly protein 3 modulates immune responses in vitro and in vivo. *Life Sciences*. 73 : 2029 – 2045. 70.Okuda, H., Kameda, K., Morimoto, C., Matsuura, Y., Chikaki, M., & Jiang, M. 1998. Studies on insulin-like substances and inhibitory substances toward angiotensin-converting enzyme in royal jelly. *Honeybee Sciences*. 19 : 9 – 14. 71.Olsson, I. L., Breitman, T. R., & Gallo, R. C. 1982. Priming of human myeloid leukemic cell lines HL-60 and U937 with retinoic acid for differentiation effects of cyclic adenosine 3' :5' -monophosphate-inducing agents a T-lymphocyte-derived differentiation factor. *Cancer Research*. 42 : 3928-3933. 72.Onozaki, K., Urawa, H., Tamatani, T., Iwamura, Y., Hashimoto, T., Baba, T., Suzuki, H., Yamada, M., Yamamoto, S., & Oppenheim, J. J. 1988. Synergistic interactions of interleukin 1, interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). Evidence that interferon-beta is an autocrine differentiating factor. *Journal of Immunology*. 140 : 112-119. 73.Paoletti, P., Butti, G., Knerich, R., Gaetani, P., & Assietti, R. 1990. Chemotherapy for malignant of brain : a review of ten-years experience. *Acta Neurochirurgical*. 103 :

- 35-46. 74.Payne, C. M., Bernstein, C., Bernstein, H., Gerner, E. W., & Garewal, H. 1999. Reactive nitrogen species in colon carcinogenesis. *Antioxidants & Redox Signalling*. 1 : 449 – 67. 75.Pestka, S, Langer, J. A., Zoon, K. C., & Samuel, C. E. 1987. Interferons and their actions. *Annual Review of Biochemistry*, 56, 727-777. 76.Post-White, J. 1996. The Immune system. *Seminars in Oncology Nursing*. 12 : 89-96. 77.Powrie, F., & Coffman, R L. 1993. Cytokine regulation of T-cell function: potential therapeutic intervention. *Immunology Today*. 14 : 270-274. 78.Ralph, P., Harris, P. E., Punjabi, C. J., Welte, K., Litcofsky, P. B., Ho, M. K., Rubin, B. Y., Moore, M. A., & Springer, T. A. 1983. Lymphokine inducing “terminal differentiation” of the human monoblast leukemia line U937: a role for interferon-. *Blood*. 62 : 1169-1175. 79.Salazar-Olivo, L.A., & Paz-Gonzales, V. 2005. Screening of biological activities present in honeybee (*Apis mellifera*) royal jelly. *Toxicology in Vitro*. 19 : 645 – 651. 80.Salgeme, P., Abrams, J. S., Clayberger, C., Goldstein, H., Convit, J., Modlin, R. L., & Bloom, B. R. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. *Science*. 254 : 279-282. 81.Schmidt, J. O. 1996. Bee products: chemical composition and application. In: Mizrahi, H., Lensky, Y. (Eds.), *Bee Products: Properties, Applications and Apitherapy*. Plenum, New York, pp. 15 – 26. 82.Schmitzova, J., Klaudiny, J., Albert, S., Schroder, W., Schreckengost, W., Hanes, J., et al. 1998. A family of major royal jelly proteins of the honeybee *Apis mellifera* L.. *Cellular and Molecular Life Sciences*. 54 : 1020 – 1030. 83.Schonleben, S., Sickmann, A., Mueller, M. J., & Reinders, J. 2007. Proteome analysis of *Apis mellifera* royal jelly. *Analytical and Bioanalytical Chemistry*. 389 : 1087 – 1093. 84.Shimoda, M., Nakajin, S., Oikawa, T., Sato, K., Kamogawa, A., & Akiyama, Y. 1978. Biochemical studies on vasodilative factor in royal jelly. *Yakugaku Zasshi*. *Journal of the Pharmaceutical Society of Japan*. 98 : 139 – 145. 85.Simuth, J. 2001. Some properties of the main protein of honeybee (*Apis mellifera*) royal jelly. *Apidologie*. 32 : 69 – 80. 86.Simuth, J., Bilikova, K., Kovacova, E., Kuzmova, Z., & Schroder, W. 2004. Immunochemical approach to detection of adulteration in honey: Physiologically active royal jelly protein stimulating TNF-alpha release is a regular component of honey. *Journal of Agricultural and Food Chemistry*. 52 : 2154 – 2158. 87.Sriskandan, S., Evans, T. J. & Cohen, J. 1996. Bacterial superantigen-induced human lymphocyte responses are nitric oxide dependent and mediated by IL-12 and INF-gamma. *Journal of Immunology*. 156 : 2430-2435. 88.Sundstrom, C., & Nilsson, K. 1976. Establishment characterization of a human histiocytic lymphoma cell line (U-937). *International Journal of Cancer. Journal International Du Cancer*. 17 : 565-577. 89.Takeda, K., minowada, J., & Bloch, A. 1993. Differential ability of mitogen-stimulated human leukocyte-conditioned media to induce Fc receptors in human leukemia cells. *Cellular Immunology*. 79 : 288-297. 90.Tamatani, T., Kimura, S., Hashimoto, T., & Onozaki, K. 1989. Purification of guinea pig tumor necrosis factor (TNF): comparison of its antiproliferative and differentiative activities for myeloid leukemic cell lines with those of recombinant human TNF. *Journal of Biochemistry*. 105 : 55-60. 91.Tamura, S., Kono, T., Harada, C., Yamaguchi, K., & Moriyama, T. 2009. Estimation and characterisation of major royal jelly proteins obtained from the honeybee *Apis merifera*. *Food Chemistry*. 114: 1491 – 1497. 92.Townsend, G. F., Morgan, J. F., & Hazlett, B. 1959. Activity of 10-hydroxydecenoic acid from royal jelly against experimental leukemia and ascitic tumors. *Nature*.183 : 1270 – 1271. 93.Townsend, G. F., Morgan, J. F., Tolnai, S., Hazlett, B., Morton, H. J., & Shuel, R. W., 1960. Studies on the in vitro antitumor activity of fatty acid I. 10-Hydroxy-2-decenoic acid from royal jelly. *Cancer Research*. 20: 503 – 510. 94.Townsend, G. F., Brown, W. H., Felauer, E. E., & Hazlett, B. 1961. Studies on the in vitro antitumor activity of fatty acid IV. The esters of acids closely related to 10-hydroxy-2-decenoic acid from royal jelly against transplantable mouse leukaemia. *Canada Journal of Biochemistry Physiology*. 39 : 1765 – 1770. 95.Wager, R. E., Scotto, L., & Assoian, R. K. 1994. Analysis of transforming growth factor beta 1 messenger RNA degradation the transcript-selective, 12-O-tetradecanoylphorbol-13-acetate-regulated ribonuclease system from U937 promonocytes. *Cell Growth & Differentiation, The Molecular Biology Journal of The American Association for Cancer Research*. 5 : 117-124. 96.Wahl, S. M., McCartney-Francis, N., Chan, J., Dionne, R. & Ta, L. 2003. Orenstein JM. Nitric oxide in experimental joint inflammation. Benefit or detriment? *Cells, Tissues, Organs*. 174 : 26-33. 97.Wang, H. X., Ng, T. B., Ooi, V. E., Liu, W. K., & Chang, S. T. 1996. A polysaccharide-peptide complex from cultured mycelia of the mushroom *Tricholoma mongolicum* with immunoenhancing and antitumor activities. *Biochemistry and Cell Biology-Biochimie et Biologie Cellulaire*. 174 : 95-100. 98.Watanabe, K., Shinmoto, H., Kobori, M., Tsushida, T., Shinohara, K., Kanaeda, J., et al. 1996. Growth stimulation with honey royal jelly DIII protein of human lymphocytic cell lines in a serum-free medium. *Biotechnology Techniques*. 10 : 959 – 962. 99.Watanabe, K., Shinmoto, H., Kobori, M., Tsushida, T., Shinohara, K., Kanaeda, J., et al. 1998. Stimulation of cell growth in the U-937 human myeloid cell line by honey royal jelly protein. *Cytotechnology*. 26 : 23 – 27. 100.Way, D. K., Qin, W., Garris, T. O., Chen, J., Hao, E., Cooper, D. R., Usals, S. J., Parker, P. K., & Cook, P. P. 1994. Effects of chronic phorbol ester treatment on protein kinase C activity, content, and gene expression in the human monoblastoid U937 cell. *Cell Growth & Differentiation. The Molecular Biology Journal of The American Association for Cancer Research*. 5 : 161-169. 101.Wang, S. Y., Hsu, M. L., Hsu, H. C., Tzeng, C. H., Lee, S. S., Shiao, M. S., & Ho, C. K. 1997. The anti-tumor effect of *Ganoderma lucidum* is mediated by cytokines released from activated macrophages and T cells. *International Journal of Cancer*. 70 : 699-705. 102.Wright, S. C., Kumar, P., Tam, A. W., Shen, N., Varma, M., & Larrick, J. W. 1992. Apoptosis and DNA fragmentation precede TNF-induced cytolysis in U937 cells. *Journal of Cellular Biochemistry*. 48 : 344-355. 103.Wu, J. P., & Ding, X. L. 2002. Characterization of inhibition, immunological properties and nutritive value of whey protein hydrolysates, *Journal of Food Protection*. 57 : 619-625. 104.Yamanaka, H., Hagiwara, K., Kirisawa, R., & Iwai, H. 2003. Proinflammatory cytokines in bovine colostrum potentiate the mitogenic response of peripheral blood mononuclear cells from newborn calves through IL-2 and CD25 expression. *Microbiological Immunology*. 47 : 461 – 468.